BROADWOOD PARTNERS, L.P. - 23 Mar 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director, 10%+ Owner
Signature
Broadwood Partners, L.P., By Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President
Issuer symbol
LCTX
Transactions as of
23 Mar 2022
Net transactions value
+$1,317,667
Form type
4
Filing time
25 Mar 2022, 17:56:24 UTC
Previous filing
01 Oct 2021
Next filing
15 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares Purchase $355,305 +260,106 +0.76% $1.37 34,265,485 23 Mar 2022 Direct F1, F2
transaction LCTX Common Shares Purchase $0 0 0% $0.000000* 34,265,485 23 Mar 2022 See Footnote F1
transaction LCTX Common Shares Purchase $284,340 +200,000 +0.58% $1.42 34,465,485 24 Mar 2022 Direct F1, F3
transaction LCTX Common Shares Purchase $0 0 0% $0.000000* 34,465,485 24 Mar 2022 See Footnote F1
transaction LCTX Common Shares Purchase $678,022 +470,000 +1.4% $1.44 34,935,485 25 Mar 2022 Direct F1, F4
transaction LCTX Common Shares Purchase $0 0 0% $0.000000* 34,935,485 25 Mar 2022 See Footnote F1
holding LCTX Common Shares 87,628 23 Mar 2022 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2 This constitutes the weighted average purchase price. The prices range from $1.33 to $1.38. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3 This constitutes the weighted average purchase price. The prices range from $1.37 to $1.44. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F4 This constitutes the weighted average purchase price. The prices range from $1.36 to $1.50. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F5 These securities are owned by Neal C. Bradsher in his personal capacity.